Imagen de Portada

Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Tereza Faitová, Christian Brieghel, Frank Eriksson, Carsten U. Niemann
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	HemaSphere
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer
por: Christian Brieghel, et al.
Publicado: (2025)

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
por: Meral Beksac, et al.
Publicado: (2026)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
por: Cristina De Ramón, et al.
Publicado: (2024)

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
por: Juan‐Jose Garces, et al.
Publicado: (2025)

Navigating the evolving management of smoldering multiple myeloma
por: M. Bakri Hammami, et al.
Publicado: (2026)

Machine learning enhances risk stratification and treatment failure prediction in diffuse large B‐cell lymphoma
por: Mikkel Werling, et al.
Publicado: (2026)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
por: Anna de Daniel, et al.
Publicado: (2024)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Publicado: (2025)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
por: Sonia Morè, et al.
Publicado: (2025)

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
por: Veronica González‐Calle, et al.
Publicado: (2024)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
por: Enrique M. Ocio, et al.
Publicado: (2024)

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant
por: Prashant R. Tembhare, et al.
Publicado: (2024)

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
por: Michael H. Tomasson, et al.
Publicado: (2024)

Correction to Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Publicado: (2025)

Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
por: Kazimierz Groen, et al.
Publicado: (2025)

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
por: Wassilis S. C. Bruins, et al.
Publicado: (2025)

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
por: Zoltán Kellermayer, et al.
Publicado: (2024)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
por: Patrick Born, et al.
Publicado: (2025)

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
por: Larissa Haertle, et al.
Publicado: (2024)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
por: Johannes Steinhart, et al.
Publicado: (2024)

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients
por: Maria Papatsirou, et al.
Publicado: (2024)

An EHA strategic roadmap for improved care in Europe for AYA patients with malignant and chronic non‐malignant hematological diseases
por: Anna Castleton, et al.
Publicado: (2026)

European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
por: Niccolò Bolli, et al.
Publicado: (2025)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
por: Ola Landgren, et al.
Publicado: (2025)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
por: Wassilis S. C. Bruins, et al.
Publicado: (2024)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
por: Benjamin A. Derman, et al.
Publicado: (2025)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
por: Andrea Manubens, et al.
Publicado: (2025)

Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
por: Hyungwoo Cho, et al.
Publicado: (2024)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
por: Niels W. C. J. van de Donk, et al.
Publicado: (2025)

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study
por: Axel André, et al.
Publicado: (2024)

Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma
por: Ramin Raoof, et al.
Publicado: (2026)

Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors
por: Lukasz Komorowski, et al.
Publicado: (2024)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
por: Eirini Katodritou, et al.
Publicado: (2025)

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
por: Elias K. Mai, et al.
Publicado: (2024)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
por: Kazimierz Groen, et al.
Publicado: (2024)

Monoclonal gammopathy of undetermined significance with multiple paraproteins: A population‐based screening study
por: Sæmundur Rögnvaldsson, et al.
Publicado: (2024)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
por: Romane Durand, et al.
Publicado: (2024)

Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies
por: Charles Agbuduwe, et al.
Publicado: (2025)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
por: Jean Galtier, et al.
Publicado: (2025)

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
por: John G. Gribben, et al.
Publicado: (2025)